Rear Admiral (Upper Half) Richard W. Childs Flag Promotion Ceremony
The United States Public Health Service Flag Promotion ceremony for Rear Admiral (RADM) Richard W. Childs, promoted to RADM Upper Half O-8 in January 2020, is being webcast live on 3/27/2020 from Masur Auditorium. Richard Childs, MD serves as the Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). He was commissioned in the USPHS Commissioned Corps as a Lieutenant in 1995 when joined the NCI as an Oncology Fellow. Following fellowship training, he was appointed a tenure-track investigator in the Hematology Branch of the NHLBI where he continues to conduct r...
Source: Videocast - All Events - February 24, 2020 Category: General Medicine Tags: Upcoming Events Source Type: video
Division of Allergy, Immunology and Transplantation Subcommittee - January 2020
Report from Division Director and Division StaffAir date: 1/27/2020 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - January 14, 2020 Category: General Medicine Tags: Upcoming Events Source Type: video
Division of Allergy, Immunology and Transplantation Subcommittee - September 2019
Report from Division Director and Divsion StaffAir date: 9/9/2019 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - August 29, 2019 Category: General Medicine Tags: Upcoming Events Source Type: video
Nanoparticle may replace biopsy needles in transplant organ rejection (Image 2)
A T cell (in purple) makes contact with a transplant organ cell (in reddish brown). The T cell secretes the enzyme granzyme B (in gray), which attacks the organ cell. But granzyme B also severs fluorescent signal molecules (in green) from the rejection-detecting nanoparticle (in light pink). The ...This is an NSF Multimedia Gallery item. (Source: NSF Multimedia Gallery)
Source: NSF Multimedia Gallery - June 20, 2019 Category: Science Source Type: video
Nanoparticle may replace biopsy needles in transplant organ rejection (Image 1)
A T cell (in violet) makes contact with a transplant organ cell (in brown and purple). The T cell secretes the enzyme granzyme B (in gray), which attacks the organ cell. But granzyme B also severs fluorescent signal molecules (in green) from the rejection-detecting nanoparticle (light red). The ...This is an NSF Multimedia Gallery item. (Source: NSF Multimedia Gallery)
Source: NSF Multimedia Gallery - June 20, 2019 Category: Science Source Type: video
Chimeric Antigen Receptor T-cell Therapies for Hematological Malignancies
CCR Grand Rounds
James Kochenderfer, M.D., is a tenure-track investigator in the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI). For the past 12 years, Dr. Kochenderfer has focused on a full range of chimeric antigen receptor (CAR) research from designing and cons tructing new CARs to conducting clinical trials. Dr. Kochenderfer designed and constructed a novel anti-CD19 CAR and then participated in a clinical trial of this CAR. This clinical trial was the first to demonstrate antigen-specific activity of anti-CD19 CARs in humans. This work in anti-CD19 CAR T cells led to...
Source: Videocast - All Events - June 10, 2019 Category: General Medicine Tags: Upcoming Events Source Type: video
Division of Allergy, Immunology and Transplantation Subcommittee - June 2019
Report from Division Director and Division StaffAir date: 6/3/2019 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - May 23, 2019 Category: General Medicine Tags: Upcoming Events Source Type: video
Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment
In this activity, based on a live symposium held during the 2019 Transplantation and Cellular Therapy (TCT) Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in hematology-oncology explore new developments related to the changing clinical consensus for managing veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) as a post-transplant complication. In this program, the panelists will share their views on VOD pathophysiology and proposed revisions to diagnostic and severity grading criteria, while ...
Source: Peerview CME/CE Video Podcast - Internal Medicine International - April 17, 2019 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Division of Allergy, Immunology, and Transplantation Subcommittee - January 2019
Report from Division Director and Division StaffAir date: 1/28/2019 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - January 9, 2019 Category: General Medicine Tags: Upcoming Events Source Type: video
Division of Allergy, Immunology and Transplantation Subcommittee - September 2018
Report from Division Director and Division StaffAir date: 9/17/2018 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - August 31, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Division of Allergy, Immunology and Transplantation Subcommittee - June 2018
Report from Division Director and Division StaffAir date: 6/4/2018 1:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - May 23, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Paul Richardson, MD - Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT
Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT (Source: Peerview CME/CE Video Podcast - Internal Medicine International)
Source: Peerview CME/CE Video Podcast - Internal Medicine International - May 22, 2018 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
Paul Richardson, MD - Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT
Integrated Myeloma Management for Transplant-Eligible Patients: The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT (Source: PeerView CME/CE Video Podcast - Oncology)
Source: PeerView CME/CE Video Podcast - Oncology - May 22, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: video
1) Hematopoietic Stem Cell Transplantation: Evolution in Understanding, Revolution in Therapy and 2) Minimizing the Scourge of Graft-Versus-Host Disease with Post-Transplantation Cyclophosphamide
For more information go tohttps://www.cc.nih.gov/about/news.htmlAir date: 5/23/2018 12:00:00 PM (Source: Videocast - All Events)
Source: Videocast - All Events - April 24, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
Inflammation and hematopoietic stem cell regulation
NIH Director ’ s Wednesday Afternoon Lecture Series
Blood-forming hematopoietic stem cells (HSC) usually remain quiescent until activated to respond to hematopoietic demands. Quiescence is an actively enforced state that is regulated by important bone marrow (BM) niche signals, which prevent entry into the cell cycle and suppress oxidative metabolism. In fact, HSC activation is as much a metabolic remodeling with oxidative phosphorylation (OXPHOS) activation, as a direct triggering of the cell-cycle machinery. It is now becoming clear that the most glycolytic and quiescent HSCs perform the best in transplantation experim...
Source: Videocast - All Events - February 20, 2018 Category: General Medicine Tags: Upcoming Events Source Type: video
